France Meningococcal Vaccines Market Insight
Published: 01 August 2026 | Report Format: Electronic (PDF) | Author: Aditi and Govind
growth rate of the meningococcal vaccines market in France is expected to grow at a rate of 5.84% owing to mandatory national immunization policies, expanding reimbursement coverage for infants and adolescents, public health campaigns against invasive meningococcal disease, and high adoption of multi-serogroup conjugate vaccines.
France Meningococcal Vaccines Market Insights Forecasts to 2035
- The France Meningococcal Vaccines Market Size Was Estimated USD 192.3 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.84% from 2025 to 2035
- The France Meningococcal Vaccines Market Size is Expected to rise around USD 339.2 Million by 2035
Notable Insights for the France Meningococcal Vaccines Market
- Based on the Segmentation by Vaccine Type, it can be observed that the Serogroup B Vaccines (Bexsero, Trumenba) segment is taking lead in France Meningococcal Vaccines Market in 2025, holding almost 51% of the total market share due to expanding mandatory vaccination mandates for infants and high incidence rates of serogroup B infections.
- Based on the Segmentation by End User, it can be seen that Public Hospitals & State Immunization Clinics segment held a market share of about 64% in France Meningococcal Vaccines Market in 2025, mainly driven by government-funded immunization schedules, National Health Insurance reimbursements, and public health procurement programs.
- The global revenue of Sanofi SA in fiscal year 2025 stood at nearly $48.2 billion backed by strong demand for pediatric vaccines, public health supply contracts, and expanding specialty care portfolios.
- Increasing implementation of mandatory MenACWY and MenB immunization schedules for infants and catch-up programs for adolescents will fuel the growth of the market in coming years, as mandatory coverage policies enhance vaccination rates up to 89% and reduce invasive meningococcal disease transmission up to 34%.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
Intelligent Market Research Based on AI for Healthcare & Preventive Medicine
Decisions Advisors offers intelligent market research which includes advanced analysis of meningococcal vaccine formulations, public health immunization policies, clinical efficacy data, and epidemiology tracking. Our research identifies potential areas of business development, vaccine adoption rates, competitive position analysis, and important strategic changes in France Meningococcal Vaccines Market.
Highly Effective Research Approaches with Accurate Forecast Analysis
The research process uses advanced methodologies such as primary research interview approaches, healthcare industry research, tracking the biopharmaceutical supply chain, and data triangulation to deliver accurate market sizing, CAGR forecasting, investment analysis, and clinical pipeline forecasting. The study examines the demand for pediatric, adolescent, and adult immunization solutions in public hospitals, private clinics, and national health agencies in France.
Highly Competitive Environment Analysis
In-depth analysis of key vaccine manufacturers, biopharmaceutical innovations, combination vaccine platforms, product launch activities, and strategic partnerships is included in the report. The report also covers French National Authority for Health (HAS) regulations, vaccine reimbursement frameworks, cold-chain distribution infrastructure, and new opportunities available in the France Meningococcal Vaccines Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Meningococcal Vaccines Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Meningococcal Vaccines Market
- Sanofi SA
- GSK plc
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Serum Institute of India Pvt. Ltd.
- Bavarian Nordic A/S
- Valneva SE
- Incepta Vaccine Ltd.
- Walvax Biotechnology Co., Ltd.
Recent Developments:
- In February 2025, GSK plc secured regulatory approval and initiated commercial expansion for its pentavalent meningococcal conjugate vaccine platform (Penmenvy) covering serogroups A, B, C, W, and Y to streamline adolescent immunization regimens.
- In January 2025, Sanofi SA and the French Ministry of Health established a strategic supply partnership to roll out mandatory MenACWY and MenB vaccines for infants under 2 years across French regional health agencies.
Market Segmentation:
France Meningococcal Vaccines Market, By Vaccine Type
- Serogroup B Vaccines (Bexsero, Trumenba)
- Quadrivalent ACWY Conjugate Vaccines (Menveo, Nimenrix, MenQuadfi)
- Pentavalent ABCWY Combination Vaccines
- Monovalent Meningococcal Conjugate Vaccines
- Polysaccharide Meningococcal Vaccines
France Meningococcal Vaccines Market, By Age Group
- Infants & Toddlers (0–2 Years)
- Children & Pre-Adolescents (3–10 Years)
- Adolescents & Young Adults (11–24 Years)
- Adults & Elderly (25 Years and Above)
France Meningococcal Vaccines Market, By End User
- Public Hospitals & State Immunization Centers
- Community Pharmacies & Retail Outlets
- Private Clinics & Pediatric Centers
- Educational Institutions & Campus Health Services
Expert Views:
The French meningococcal vaccines market will experience sustained growth owing to mandatory national immunization policies, expanding reimbursement coverage, and high public awareness surrounding invasive meningococcal disease prevention. The integration of pentavalent conjugate vaccines, extended adolescent catch-up programs, and streamlined pediatric schedules will enhance immunization coverage and drive strong market demand across public healthcare systems, clinical networks, and community pharmacy networks throughout France.
Author: Aditi and Govind By Decisions Advisors and Consulting